Comparison of patients with small (≤2 cm) breast cancer according to adherence to breast screening program

Jung Min Park, Soong Jun Bae, Changik Yoon, Hye Sun Lee, Hak Woo Lee, Sung Gwe Ahn, Seung Ah Lee, Joon Jeong

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: We investigated whether adherence to breast screening would yield a clinical benefit even among patients with small breast cancer (≤2 cm) by comparing differences between those who did and did not adhere to breast screening. Methods: Patients who were diagnosed with invasive T1 breast cancer and treated at Gangnam Severance Hospital from January 2006 to June 2014 were included. Of the 632 study patients, 450 and 182 were classified as screen-adherent and non-adherent. Adherence to the breast screening program was defined as the completion of breast screening examinations within 3 years before cancer diagnosis. Recurrence-free survival (RFS) and metastasis-free survival (MFS) were compared between the groups. Propensity score matching were applied to compare survival outcome. Results: Adherent patients were more likely to have a lower histologic grade (P < 0.001), high estrogen receptor expression (P = 0.040), and lower HER2-positivity (P = 0.026). The adherent group had more favorable subtypes compared to the non-adherent group, with a greater percentage of Luminal/HER2-negative subtype (66.7% vs. 56.5%) and a lower percentage of HER2 subtype (8.3% vs. 16.7%). The RFS and MFS were significantly better in the adherent group (P = 0.003, 0.010, respectively). In the case-matched cohort, superior survival of the adherent group was maintained. Conclusions: Adherence to breast screening in patients with small breast tumors was associated with more favorable tumor biology and better prognosis. Our findings suggest that adherence to breast screening might offer clinical benefits in terms of tumor biology as well as early detection.

Original languageEnglish
Article numbere0186988
JournalPloS one
Volume12
Issue number11
DOIs
Publication statusPublished - 2017 Nov

Fingerprint

breast neoplasms
breasts
Screening
Breast
Breast Neoplasms
screening
Survival
Tumors
metastasis
neoplasms
Neoplasm Metastasis
Recurrence
Biological Sciences
Neoplasms
Propensity Score
Phenobarbital
Estrogen Receptors
prognosis

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Park, Jung Min ; Bae, Soong Jun ; Yoon, Changik ; Lee, Hye Sun ; Lee, Hak Woo ; Ahn, Sung Gwe ; Lee, Seung Ah ; Jeong, Joon. / Comparison of patients with small (≤2 cm) breast cancer according to adherence to breast screening program. In: PloS one. 2017 ; Vol. 12, No. 11.
@article{8696710744694bb99a0b5195f6f8771c,
title = "Comparison of patients with small (≤2 cm) breast cancer according to adherence to breast screening program",
abstract = "Background: We investigated whether adherence to breast screening would yield a clinical benefit even among patients with small breast cancer (≤2 cm) by comparing differences between those who did and did not adhere to breast screening. Methods: Patients who were diagnosed with invasive T1 breast cancer and treated at Gangnam Severance Hospital from January 2006 to June 2014 were included. Of the 632 study patients, 450 and 182 were classified as screen-adherent and non-adherent. Adherence to the breast screening program was defined as the completion of breast screening examinations within 3 years before cancer diagnosis. Recurrence-free survival (RFS) and metastasis-free survival (MFS) were compared between the groups. Propensity score matching were applied to compare survival outcome. Results: Adherent patients were more likely to have a lower histologic grade (P < 0.001), high estrogen receptor expression (P = 0.040), and lower HER2-positivity (P = 0.026). The adherent group had more favorable subtypes compared to the non-adherent group, with a greater percentage of Luminal/HER2-negative subtype (66.7{\%} vs. 56.5{\%}) and a lower percentage of HER2 subtype (8.3{\%} vs. 16.7{\%}). The RFS and MFS were significantly better in the adherent group (P = 0.003, 0.010, respectively). In the case-matched cohort, superior survival of the adherent group was maintained. Conclusions: Adherence to breast screening in patients with small breast tumors was associated with more favorable tumor biology and better prognosis. Our findings suggest that adherence to breast screening might offer clinical benefits in terms of tumor biology as well as early detection.",
author = "Park, {Jung Min} and Bae, {Soong Jun} and Changik Yoon and Lee, {Hye Sun} and Lee, {Hak Woo} and Ahn, {Sung Gwe} and Lee, {Seung Ah} and Joon Jeong",
year = "2017",
month = "11",
doi = "10.1371/journal.pone.0186988",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

Comparison of patients with small (≤2 cm) breast cancer according to adherence to breast screening program. / Park, Jung Min; Bae, Soong Jun; Yoon, Changik; Lee, Hye Sun; Lee, Hak Woo; Ahn, Sung Gwe; Lee, Seung Ah; Jeong, Joon.

In: PloS one, Vol. 12, No. 11, e0186988, 11.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of patients with small (≤2 cm) breast cancer according to adherence to breast screening program

AU - Park, Jung Min

AU - Bae, Soong Jun

AU - Yoon, Changik

AU - Lee, Hye Sun

AU - Lee, Hak Woo

AU - Ahn, Sung Gwe

AU - Lee, Seung Ah

AU - Jeong, Joon

PY - 2017/11

Y1 - 2017/11

N2 - Background: We investigated whether adherence to breast screening would yield a clinical benefit even among patients with small breast cancer (≤2 cm) by comparing differences between those who did and did not adhere to breast screening. Methods: Patients who were diagnosed with invasive T1 breast cancer and treated at Gangnam Severance Hospital from January 2006 to June 2014 were included. Of the 632 study patients, 450 and 182 were classified as screen-adherent and non-adherent. Adherence to the breast screening program was defined as the completion of breast screening examinations within 3 years before cancer diagnosis. Recurrence-free survival (RFS) and metastasis-free survival (MFS) were compared between the groups. Propensity score matching were applied to compare survival outcome. Results: Adherent patients were more likely to have a lower histologic grade (P < 0.001), high estrogen receptor expression (P = 0.040), and lower HER2-positivity (P = 0.026). The adherent group had more favorable subtypes compared to the non-adherent group, with a greater percentage of Luminal/HER2-negative subtype (66.7% vs. 56.5%) and a lower percentage of HER2 subtype (8.3% vs. 16.7%). The RFS and MFS were significantly better in the adherent group (P = 0.003, 0.010, respectively). In the case-matched cohort, superior survival of the adherent group was maintained. Conclusions: Adherence to breast screening in patients with small breast tumors was associated with more favorable tumor biology and better prognosis. Our findings suggest that adherence to breast screening might offer clinical benefits in terms of tumor biology as well as early detection.

AB - Background: We investigated whether adherence to breast screening would yield a clinical benefit even among patients with small breast cancer (≤2 cm) by comparing differences between those who did and did not adhere to breast screening. Methods: Patients who were diagnosed with invasive T1 breast cancer and treated at Gangnam Severance Hospital from January 2006 to June 2014 were included. Of the 632 study patients, 450 and 182 were classified as screen-adherent and non-adherent. Adherence to the breast screening program was defined as the completion of breast screening examinations within 3 years before cancer diagnosis. Recurrence-free survival (RFS) and metastasis-free survival (MFS) were compared between the groups. Propensity score matching were applied to compare survival outcome. Results: Adherent patients were more likely to have a lower histologic grade (P < 0.001), high estrogen receptor expression (P = 0.040), and lower HER2-positivity (P = 0.026). The adherent group had more favorable subtypes compared to the non-adherent group, with a greater percentage of Luminal/HER2-negative subtype (66.7% vs. 56.5%) and a lower percentage of HER2 subtype (8.3% vs. 16.7%). The RFS and MFS were significantly better in the adherent group (P = 0.003, 0.010, respectively). In the case-matched cohort, superior survival of the adherent group was maintained. Conclusions: Adherence to breast screening in patients with small breast tumors was associated with more favorable tumor biology and better prognosis. Our findings suggest that adherence to breast screening might offer clinical benefits in terms of tumor biology as well as early detection.

UR - http://www.scopus.com/inward/record.url?scp=85033370512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033370512&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0186988

DO - 10.1371/journal.pone.0186988

M3 - Article

C2 - 29095835

AN - SCOPUS:85033370512

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e0186988

ER -